ReviewPhilosophical transactions of the Royal Society of London. Series B, Biological sciences2015
Treatment of Parkinson's disease using cell transplantation.
Review in Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05699161 (Treatment of Parkinson Disease With Transplantation of SVF Cells of Adipose Origin), which is not on this map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Treatment of Parkinson Disease With Transplantation of SVF Cells of Adipose Origin: Safety and Exploratory Efficacy Study
Who cites it
30 citing papers in PubMed, 78 citations in OpenAlex.
- Neural stem cells transplantation combined with ethyl stearate promotes the activation of quiescent NSCs and improves PD rats motor behavior.Animal models and experimental medicine · 2026Article
- Differentiation and functional connectivity of fetal tectal transplants.Neural regeneration research · 2023Article
- Olfactory ensheathing cells and neuropathic pain.Frontiers in cell and developmental biology · 2023Review
- Potential injectable hydrogels as biomaterials for central nervous system injury: A narrative review.Ibrain · 2023Review
- Functional differentiation of the dorsal striatum: a coordinate-based neuroimaging meta-analysis.Quantitative imaging in medicine and surgery · 2023Article
- Current Status and Future Perspectives on Stem Cell-Based Therapies for Parkinson's Disease.Journal of movement disorders · 2023Article
- The understanding of Parkinson's disease through genetics and new therapies.Brain and behavior · 2022Article
- Non-Immersive Virtual Reality to Improve Balance and Reduce Risk of Falls in People Diagnosed with Parkinson's Disease: A Systematic Review.Brain sciences · 2021Review
- The BDNF Val66Met polymorphism (rs6265) enhances dopamine neuron graft efficacy and side-effect liability in rs6265 knock-in rats.Neurobiology of disease · 2021Article
- Therapeutic Potential ofParkinson's disease · 2021Review
- Molecular Communication Between Neuronal Networks and Intestinal Epithelial Cells in Gut Inflammation and Parkinson's Disease.Frontiers in medicine · 2021Review
- Microencapsulated Neural Stem Cells Inhibit Sciatic Nerve Injury-Induced Pain by Reducing P2 × 4 Receptor Expression.Frontiers in cell and developmental biology · 2021Article
- Stem Cell-Based Therapies in Hearing Loss.Frontiers in cell and developmental biology · 2021Review
- Grafted human pluripotent stem cell-derived cortical neurons integrate into adult human cortical neural circuitry.Stem cells translational medicine · 2020Article
- Parkinson's disease treatment: past, present, and future.Journal of neural transmission (Vienna, Austria : 1996) · 2020Review
- Bioluminescence-driven optogenetic activation of transplanted neural precursor cells improves motor deficits in a Parkinson's disease mouse model.Journal of neuroscience research · 2020Article
- Neuronal Replacement as a Tool for Basal Ganglia Circuitry Repair: 40 Years in Perspective.Frontiers in cellular neuroscience · 2020Review
- The Future of GDNF in Parkinson's Disease.Frontiers in aging neuroscience · 2020Article
- Strategies for the Treatment of Parkinson's Disease: Beyond Dopamine.Frontiers in aging neuroscience · 2020Article
- A Gutsy Move for Cell-Based Regenerative Medicine in Parkinson's Disease: Targeting the Gut Microbiome to Sequester Inflammation and Neurotoxicity.Stem cell reviews and reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinical trials with intrastriatal transplantation of human fetal mesencephalic tissue, rich in dopaminergic neurons, in Parkinson's disease (PD) patients show that cell replacement can work and in some cases induce major, long-lasting improvement. However, owing to poor tissue availability, this approach can only be applied in very few patients, and standardization is difficult, leading to wide variation in functional outcome. Stem cells and reprogrammed cells could potentially be used to produce dopaminergic neurons for transplantation. Importantly, dopaminergic neurons of the correct substantia nigra phenotype can now be generated from human embryonic stem cells in large numbers and standardized preparations, and will soon be ready for application in patients. Also, human induced pluripotent stem cell-derived dopaminergic neurons are being considered for clinical translation. Available data justify moving forward in a responsible way with these dopaminergic neurons, which should be tested, using optimal patient selection, cell preparation and transplantation procedures, in controlled clinical studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.